3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Head and Neck Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Breast Neoplasms
2
Zollinger-Ellison Syndrome
1
Uterine Cervical Dysplasia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Obesity
1
Mouth Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammation
1
Gastrinoma
1
Colorectal Neoplasms
1
Chemotherapy Effect
1
Burkitt Lymphoma
1
Interventions
Abiraterone Acetate
5
enzalutamide
4
abiraterone
3
Prednisone
3
apalutamide
2
Nivolumab
2
Docetaxel
2
pembrolizumab
1
niraparib
1
darolutamide
1
cabazitaxel
1
Pluvicto
1
Omeprazole
1
Ipilimumab
1
Drug Therapy
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms, Castration-Resistant
×
Omeprazole
×
Clear all
NCT04337580
2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2
Recruiting
50 enrolled